An Exploratory Research of Soluble B7-H3 Expression in Peripheral Blood as a Biomarker to Monitor Therapeutic Effect of Systemic Treatment for Osteosarcoma
Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY
Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable prognosis in patients with malignancies. However, the level of sB7-H3 and its clinical significance in osteosarcoma are not well known. In this present study, we investigated whether sB7-H3 levels in serum could be as a biomarker for osteosarcoma treatment.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Healthy Volunteers: f
View:
• High Grade osteosarcoma verified with pathologic diagnosis.
• systemic treatment-naive before the first time Blood drawing.
• ECOG 0 or 1 and all the other imagings indicate that patients could tolerate standard PKUPH-OS-02 protocol neoadjuvant chemotherapy.
• All radiographs are complete for clinical evaluation.
Locations
Other Locations
China
Peking University People's Hospital
RECRUITING
Beijing
Contact Information
Primary
Lu Xie, M.D.
xie.lu@hotmail.com
+86-13401044719
Time Frame
Start Date: 2023-06-05
Estimated Completion Date: 2024-12-31
Participants
Target number of participants: 200
Treatments
sB7-H3 of treatment-naive osteosarcoma patients
Before delivering neoadjuvant chemotherapy, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood
sB7-H3 after neoadjuvant chemotherapy for osteosarcoma patients
After neoadjuvant chemotherapy and before definitive surgery, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood
Related Therapeutic Areas
Sponsors
Leads: Peking University People's Hospital